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The presence of circulating tumor cells (CTCs) in the peripheral blood is a pre-requisite
for progression, invasion, and metastatic spread of cancer. Consequently, the
enumeration and molecular characterization of CTCs from the peripheral blood of
patients with solid tumors before, during and after treatment serves as a valuable
tool for categorizing disease, evaluating prognosis and for predicting and monitoring
therapeutic responsiveness. Many of the techniques for isolating CTCs are based on
the expression of epithelial cell surface adhesion molecule (EpCAM, CD326) on tumor
cells. However, the transition of adherent epithelial cells to migratory mesenchymal
cells (epithelial-to-mesenchymal transition, EMT)—an essential element of the metastatic
process—is frequently associated with a loss of expression of epithelial cell markers,
including EpCAM. A highly relevant proportion of mesenchymal CTCs cannot therefore
be isolated using techniques that are based on the “capture” of cells expressing EpCAM.
Herein, we provide evidence that a monoclonal antibody (mAb) directed against a
membrane-bound form of Hsp70 (mHsp70)—cmHsp70.1—can be used for the isolation
of viable CTCs from peripheral blood of tumor patients of different entities in a more
quantitative manner. In contrast to EpCAM, the expression of mHsp70 remains stably
upregulated on migratory, mesenchymal CTCs, metastases and cells that have been
triggered to undergo EMT. Therefore, we propose that approaches for isolating CTCs
based on the capture of cells that express mHsp70 using the cmHsp70.1 mAb are
superior to those based on EpCAM expression.
Keywords: circulating tumor cells (CTCs), membrane Hsp70, cmHsp70.1 antibody, EpCAM (CD326),
epithelial-to-mesenchymal transition (EMT)
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INTRODUCTION
The malignancy of solid tumors is determined by the
heterogeneity of the individual tumor (1) and its capacity
to disseminate from the primary tumor to secondary sites via
the blood stream. This process involves fundamental activities
including invasion of the extracellular matrix and surrounding
stroma, migration, evasion from the vasculature, proliferation,
and the avoidance of anoikis (a form of programmed cell death
that occurs in anchorage-dependent cells when they detach
from the surrounding extracellular matrix) (2). Due to multiple
selection steps, primary tumors and corresponding metastases
often differ in molecular markers and pathways (3). Interrogating
the biology of CTCs and also circulating tumor cell aggregates,
which are generally considered as precursors of metastasis
(4), is likely to provide invaluable insights into the biology
of the disease and the prevalence and heterogeneity of future
metastasis and thereby help to predict outcome and identify new
tumor biomarkers that could be targeted by individualized anti-
tumor therapies (5). Isolation, enumeration and the molecular
characterization of CTCs could therefore bridge the “missing
link” between cancer biology and individualized/precision
therapies. As a liquid biopsy, CTCs do not only provide an
opportunity to identify therapeutic targets and resistance
mechanisms and monitor therapeutic responsiveness, but can
also provide prognostic information about the risk of developing
metastatic relapse and tumor progression which underpin 90%
of cancer-related deaths (6–8).
A major limitation to the application of CTC-based analysis
is the rarity of this cell type in the peripheral blood. Typically,
1ml of peripheral blood of patients with metastatic cancer
contains<10 CTCs (9–11). As a consequence, different strategies
including filtration- (12, 13), microfluidic chip- (14–17), PCR-
(18–20), and flow cytometry-based techniques (21) have been
developed to enrich, separate and differentiate CTCs in the
peripheral blood from the vastly more prominent hematopoietic
cell population (1 CTC in 106-108 hematopoietic cells). Although
a variety of biomarkers such as CD44, CD133, CD47, cMET,
EGFR, and immune checkpoint inhibitors are heterogeneously
expressed on CTCs derived from different tumor entities, the
most common techniques for the ex vivo separation of CTCs
from peripheral blood are based on the capturing of cells
using antibodies directed against cell surface expressed EpCAM
(CD326) (22–26). The CellSearch R© system (27)—the FDA-
approved “gold standard”—combines a magnetic separation
technique based on EpCAM antibody-coated particles with
subsequent cytokeratin (CK) staining and a microscopic analysis
of the isolated cells (22). Another limitation of most ex vivo CTC
isolation techniques is the relatively small blood sample volume
(7.5ml) which is used and the low numbers of CTCs that can
be derived therefrom. To overcome these disadvantages of ex
vivo CTC isolation, GILUPI GmbH (Potsdam, Germany) has
developed an EpCAM antibody-coated CellCollector R© system
Abbreviations: CK, cytokeratin; CTC(s), circulating tumor cell(s); EMT,
epithelial-to-mesenchymal transition; EpCAM, epithelial cell adhesion molecule;
Hsp70, heat shock protein 70; mAb, monoclonal antibody; mHsp70, membrane-
bound form of Hsp70
which involves the direct insertion of a stainless steel wire,
functionalized with gold and a hydrogel coating that incorporates
anti-EpCAM antibodies, into the blood stream via a standard
venous cannula in the cubital veins for 30min. During this
period, CTCs can be captured from the entire peripheral blood
compartment (several liters of blood) of a cancer patient.
Subsequently, the captured viable cells can be stained whilst
attached to the wire and analyzed by fluorescence microscopy
(28) or expanded for further analysis. The number of CTCs
captured by the CellCollector R© system before and after therapy
has been shown to be associated with prognosis and therapeutic
responsiveness (11).
All the techniques described above rely on the cell surface
expression of EpCAM and the lack of the leukocyte marker
CD45 by CTCs. However, many studies have shown that the
transition of the adherent epithelial cells to the migratory
mesenchymal state which enables the motility and invasiveness
of CTCs and their dissemination to distant sites is associated
with a loss in the expression of classical epithelial cell markers,
including EpCAM (29). Yu et al. demonstrated that benign and
non-invasive tumor cells exclusively express epithelial antigens,
whereas a subpopulation of invasive breast cancer cells express
both epithelial and mesenchymal markers (30). Epithelial-to-
mesenchymal transition (EMT) correlates with an increased
migratory and metastatic potential of CTCs, invasiveness, poor
overall survival and drug resistance (29, 30). It is therefore
apparent that systems for isolating CTCs that rely only on the
expression of epithelial markers by target cells are limited in their
ability to detect CTCs arising after EMT.
The search for universal tumor markers has revealed that
the major stress-inducible heat shock protein 70 (Hsp70) is
frequently expressed on the plasma membrane of primary
tumor cells and distant metastases (31). This membrane Hsp70
(mHsp70) positivity has been identified on a large variety of
different primary tumor types such as breast, lung, head and
neck, colorectal, pancreas, brain and hematological malignancies,
but not on corresponding normal cells and tissues (32, 33).
A comparison of the cell surface density of Hsp70 has also
revealed higher intensities of mHsp70 on metastases compared
to corresponding primary tumors in mouse and human models
(33–36). This finding provides a first indication that the
expression of mHsp70 might not be downregulated by EMT
and that it could therefore serve as a useful target for the
isolation of CTCs in the circulation that have undergone EMT.
Given that our group has developed a unique mouse monoclonal
antibody (mAb) termed cmHsp70.1 which specifically detects
the membrane-bound form of Hsp70 on viable tumor cells (37),
herein we determine the capacity of the cmHsp70.1 mAb to
form the basis of improved bead- and wire-based CTC isolation
techniques that exploit mHsp70 expression as a universal tumor-
specific biomarker.
MATERIALS AND METHODS
Ethics, Patient Characteristics
Signed informed consent was obtained from all patients with
squamous cell carcinoma of the head and neck (SCCHN) and
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non-small cell lung carcinoma (NSCLC) before EDTA blood (1–
2 × 7.5ml) was taken and the protocol was approved by the
institutional ethical review board of the Klinikum rechts der Isar
at the Technische Universität München (TUM). Eight patients
with SCCHN in tumor stages pT1 to pT3, one patient with
cancer of unknown primary (CUP) tumor of the head and neck,
and three patients with advanced adenocarcinoma of the lung
(NSCLC) were included into the study.
Cell Lines and Culture
Studies undertaken at the Technische Universität München used
the following human cell lines: breast cancer cell lines MDA-MB-
231 (ATCC HTB-26), MCF7 (ATCC HTB-22), SK-BR-3 (ATCC
HTB-30), and T47D (ATCC HTB-133), lung cancer cell lines
EPLC-272H (DSMZ ACC-383), H1339 (DSMZ ACC-506), A549
(ATCC CCL-185), melanoma cell line LS174T (ATCC CL-188,
kindly provided by Professor Marina Kreutz, University Hospital
Regensburg, Germany), pancreatic cancer cell lines PANC-1
(ATCC CRL-1469), MIA PaCa-2 (ATCC CRL-1420), cervical
cancer cell line HeLa (ATCC CCL-2), colon cancer cell line HCT-
15 (ATCCCCL-225), brain cancer cell lines LN-229 (ATCCCRL-
2611), U-87 (ATCC HTB-14), squamous cell carcinoma cell lines
of the head and neck UP154, UD5 (kindly provided by Professor
Anja Pickhard, Department of Otolaryngology Head and Neck
Surgery, Klinikum rechts der Isar, TUM), prostate cancer cell
line DU145 (ATCC HTB-81). Studies undertaken at Nottingham
Trent University used the following human cell lines: breast
cancer cell lines MDA-MB-231 (ATCC HTB-26), MCF7
(ATCC HTB-22), SK-BR-3 (ATCC HTB-30) and T47D (ATCC
HTB-133), lung cancer (A549) and prostate cancer DU145
(ATCC HTB-81).
All cells were maintained under standard conditions (37◦C,
95% v/v humidity, 5% v/v CO2) in appropriate cell culture
medium. Cell line authentication was performed by DNA
profiling using highly polymorphic short tandem repeats
(DSMZ-Deutsche Sammlung von Mikroorganismen und
Zellkulturen, Leipzig, Germany (TUM) and the ATCC Cell Line
Authentication Service (NTU). Cells were passaged every 3–4
days and used in the exponential growth phase. Cell viability
was confirmed prior to use using trypan blue dye exclusion
(>95%). Cell cultures were routinely tested to ensure the absence
of mycoplasma.
Influence of TGFβ-Induced
Epithelial-to-Mesenchymal Transition
(EMT) on mHsp70 and EpCAM (CD326)
Expression
EMT was induced in DU145 prostate, UP154, and UD5
squamous cell carcinoma cells of the head and neck and A549
lung cancer cells by treatment with TGFβ (38). For this, after
initial seeding, cells were allowed to adhere for 24 h, after
which the medium was exchanged with medium containing
10 ng/ml TGFβ (PeproTech) every second day. Control cells
were sham treated in standard cell culture medium. After 10
days of cell culture with regular media changes, cells were
harvested and the expression of mHsp70 and EpCAM on viable
cells was determined by 2-color flow cytometry, as detailed
below.
Photomicroscopic views were taken from untreated and TGFβ
(10 ng/ml) treated A549 cells on day 10, day 10+ 4 days recovery
without TGFβ and day 10+ 7 days recovery without TGFβ.
Influence of L-Lactic-Acid-Induced
Epithelial-to-Mesenchymal Transition
(EMT) on mHsp70 and EpCAM (CD326)
Expression
In addition to TGFβ, EMT was induced in A549 lung cancer
cells, LS174T melanoma cells and UP154 and UD5 squamous
cell carcinoma cells of the head and neck by a treatment
with L-lactic-acid (Lac-Ac). For this, after initial seeding, cells
were incubated with medium containing L-lactic-acid (Lac-Ac,
10mM; pH 6.8). Up to a concentration of 20mM, L-lactic-acid
did not induce significant cell death in tumor cells. After 2 days,
when cells reached a confluency of 70–80% cells were harvested
and analyzed for the expression of EpCAM (CD326) andmHsp70
by flow cytometry. Control cells were sham treated with standard
culture medium.
Flow Cytometric Analysis of Membrane
Hsp70 (mHsp70) and EpCAM (CD326)
Expression
At the Technische Universität München, flow cytometric analysis
for the expression of mHsp70 and EpCAM on tumor cell lines
was undertaken using either an FITC-conjugated cmHsp70.1
mAb (multimmune GmbH, Munich, Germany) and a FITC-
conjugated EpCAM (CD326, clone HEA125) and PE-conjugated
EpCAM (CD326, clone G8.8) mAb (Acris GmbH, an OriGene
Company, Herford, Germany). Briefly, cells (1 × 105) were
incubated with the relevant antibody for 30min at 4◦C, washed
once and viable cells (propidium iodide negative) were analyzed
using a FACSCaliburTM flow cytometer (BD Biosciences, Franklin
Lakes, NJ, USA). An isotype-matched (IgG1) control antibody
(BD Biosciences) was used to evaluate non-specific binding to
cells.
At Nottingham Trent University, the co-expression of
mHsp70 and EpCAM on A549 and DU145 cells that had
been induced to undergo EMT by treatment with TGFβ
was determined by incubating cells (1 × 105) with a
FITC-conjugated cmHsp70.1 mAb (multimmune GmbH), a
PerCP-Vio770 conjugated EpCAM (CD326) mAb (Miltenyi
Biotec, Clone REA764), and LIVE/DEADTM Fixable Yellow
Dead Cell Stain (Invitrogen) at 4
◦
C for 30min. Unstained
cells, cells incubated with an isotype-matched control mAb and
cells incubated with an FITC-conjugated mAb recognizing an
epitope of Hsp70 which is inaccessible on the cell surface (clone
C92, Stressgen Biotechnologies Corpn., Victoria, Canada) served
as controls. After incubation, cells were washed once and the
expression of mHsp70 and EpCAM (CD326) by viable cells was
determined using a 3-laser, 10-color Beckman Coulter GalliosTM
flow cytometer and KaluzaTM software.
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Collection of Peripheral Blood and
Isolation of Peripheral Blood Mononuclear
Cells (PBMCs) Using Ficoll
Blood was collected from healthy volunteers into K3 EDTA tubes
(S-Monovette, Sarstedt, Nümbrecht, Germany) and mixed with
at least an equal amount of RPMI 1640 (Sigma-Aldrich, St.
Louis, USA) medium. For bead-based cell isolation experiments
(see below), harvested tumor cells which had been washed
once with phosphate-buffered saline (PBS) were added to the
anticoagulated whole blood at the indicated concentrations.
Peripheral blood mononuclear cells (PBMCs) and tumor
cells were then isolated using a Ficoll-based density gradient
lymphocyte separation medium (LSM 1077) (GE Healthcare,
Chalfont St. Giles, UK). Following centrifugation at 850 g at
room temperature (RT) for 20min, PBMCs and tumor cells
were carefully extracted from the interphase between the plasma
and the separation solution. The cells were washed twice in
medium. For further experiments (see below), cells were allowed
to recover under rotation in 10% v/v fetal bovine serum (FBS,
Sigma-Aldrich, St. Louis, USA) in PBS for 4 h.
Cell Isolation With Magnetic Dynabeads
Coupling the cmHsp70.1 mAb or EpCAM mAb (CD326, clone
HE125) to magnetic DynabeadsTM (Thermo Fisher, Waltham,
USA) was carried out according to the manufacturer’s protocol.
Dynabeads coupled with cmHsp70.1 mAb were washed and
incubated either with tumor cells, a mixture of tumor cells
and lymphocytes or EDTA blood (7.5ml) of patients with
squamous cell carcinoma of the head and neck (SCCHN)
and non-small cell lung carcinoma (NSCLC) after removal
of red blood cells for 10min at 4◦C under rotation. The
tube was placed in a DynaMagTM magnet and beads were
separated from the supernatant after a washing step. The
isolated CTCs were counted and stained with DAPI (4
′
,6-
diamidino-2-phenylindole), cytokeratin-Alexa 488, EpCAM-PE
and cmHsp70.1-FITC mAb. Isolated CTCs from tumor patients
were clonally seeded in 96-well round-bottom culture plates.
Cell Capture and Analysis on the GILUPI
CellCollector®
For determining the capacity of the GILUPI CellCollector R©
(GILUPI GmbH, Potsdam, Germany) to capture tumor cells,
cells were either pre-stained with the VybrantTM CFDA Cell
Tracer Kit (Thermo Fisher, Waltham, USA) or stained on the
wire after cell capture. 2ml reaction tubes (Sarstedt, Nürmbrecht,
Germany) were blocked with 3% w/v bovine serum albumin
(BSA, Sigma-Aldrich, St. Louis, USA) in PBS (Sigma-Aldrich, St.
Louis, USA) for 30min. Tumor cell number was adjusted to 1
× 105 cells/ml in PBS or blood from healthy human volunteers
and the reaction tube completely filled. A cmHsp70.1 mAb-
coated detector (kindly provided by GILUPI GmbH, Potsdam,
Germany) was placed in a silicone stopper and incubated with
the cell suspension for 30min under rotation. After four washing
steps, unstained cells were fixed with acetone for 30 s and blocked
with 3% w/v BSA in PBS for 30min. Cells were stained with
a cocktail of cytokeratin antibodies at RT for 30min in the
dark: CK7 (LP5K, Millipore, Billerica, USA), CK19 (A53-B/A2,
Exbio, Vestec, Czech Republic), and panCK (4–6, 8, 10, 13, 18)
(C11, Exbio, Vestec, Czech Republic). After a washing step,
cell nuclei were stained with Hoechst 33342 (Thermo Fisher
Scientific, Waltham, USA) for 5min at RT. The presence of cells
on the CellCollector R© detector was analyzed with the Zeiss Axio
Imager.M2 or the Axio Observer.Z1 (Zeiss, Jena, Germany). Cells
were counted on two sides of the wire, after a rotation of 180◦.
Image analysis and processing was performed using AxioVision
SE64 Rel. 4.9. For the transfer of captured cells back into cell
culture, the tip of an unfixed detector was cut off and incubated
in a flask with the appropriate cell culture medium.
RESULTS
mHsp70 and EpCAM Expression Varies in
Different Tumor Cell Types, but Remains
Stable After TGFβ- and L-Lactic-
Acid-Induced EMT
Hsp70 is frequently expressed on the membrane of primary
tumor cells from a variety of different entities (32–34,
36), and expression has been shown to be increased by
radio(chemo)therapy and to be of a much higher density on
distant metastases (31, 36). As EpCAM is currently the most
widely used cell surface marker for antibody-based isolation
techniques of CTCs, herein we compared mHsp70 and EpCAM
expression by tumor cell lines derived from different entities
including breast, lung, melanoma, pancreas, cervix, colon, brain,
and squamous cell carcinoma of the head and neck by flow
cytometry.
As shown in Figure 1, the LN-229 (mHsp70: 80 ± 4%),
U-87 (mHsp70: 96 ± 4%) brain, and MIA PaCa-2 (mHsp70:
97 ± 3%) pancreas tumor cells are only positive for mHsp70,
but negative for EpCAM. Within the breast cancer cell lines,
which are epithelial cells derived from metastatic sites, MDA-
MB-231 cells (basal ER− PR− HER2−), MCF7 (luminal ER+
PR+ HER2−), and T47D (luminal ER+ PR+ HER2−) exhibited
a lower expression of mHsp70 compared to EpCAM, whereas
SK-BR-3 cells (luminal ER− PR− HER2+) expressed a high
expression intensity of both markers, mHsp70 and EpCAM
(mHsp70: 95± 4%, EpCAM: 96± 7%). The patterns of mHsp70
and EpCAM expression by MDA-MB-231 (mHsp70: 50 ± 3%,
EpCAM: 90 ± 2%), MCF7 (mHsp70: 51 ± 6%, EpCAM: 99 ±
4%), and T47D (mHsp70: 25 ± 7%, EpCAM: 98 ± 5%) breast
cancer cells that were analyzed at TUM and NTU were nearly
identical (data not shown).
Heterogeneities in the expression pattern of mHsp70 and
EpCAM were also observed for human lung (EPLC-272-H,
H1339, A549), melanoma (LS174T), pancreatic (PANC-1, MIA
PaCa-2), cervix (HeLa), colon (HCT-15), brain (LN-229, U-87),
and head and neck (UP154, UD5) cancer cell lines (Figure 1).
In order to simulate EMT in vitro, prostate (DU145), head and
neck (UP154, UD5) and lung (A549) cancer cells and malignant
melanoma (LS174T) cells were incubated with TGFβ for 10
days and with L-lactic-acid (Lac-Ac, 10mM, pH 6.8) for 2 days.
Although TGFβ treatment drastically reduced the expression of
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FIGURE 1 | Membrane Hsp70 and EpCAM expression by different cancer cell lines. Cell lines from different cancer entities (breast, lung, melanoma, pancreas, cervix,
colon, brain, head, and neck) were screened for their expression of mHsp70 and EpCAM using flow cytometry. Gray histograms represent isotype control, white
histograms mHsp70 staining and black histograms EpCAM staining. The numbers in the histograms indicate the proportion of cells stained positively for mHsp70 and
EpCAM. The data show one representative result of at least three independent experiments.
EpCAM by DU145 cells (64 ± 5% to 18 ± 1%) (Figure 2A) and
A549 (62± 1% to 2± 1%) cells (Figure 2B), mHsp70 expression
was retained at nearly 100% after the induction of EMT in both
cell lines (Figures 2A,B). Similar results were observed after a
treatment of UP154 and UD5 head and neck cancer cells with
TGFβ for 10 days (data not shown) and L-lactic-acid for 2 days
(Figure 2A).
A comparative analysis of the mHsp70 and EpCAM
expression on non-adherent and adherent A549 (Figure 2B)
cells revealed a higher expression of EpCAM on the adherent,
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FIGURE 2 | Influence of TGFβ- and L-lactic-acid (Lac-Ac)-induced EMT on mHsp70 and EpCAM expression by DU145 (prostate), UP154 (head and neck), UD5
(head and neck), A549 (lung) cancer cells, and LS174T melanoma cells. (A) DU145 cells were cultured with TGFβ for 10 days, UP154 and UD5 cells were cultured for
2 days with L-lactic-acid (Lac-Ac), after which the expression of mHsp70 and EpCAM was determined. (B) A549 and LS174T cells were cultured either with TGFβ for
10 days or with L-lactic-acid (Lac-Ac) for 2 days, after which the expression of mHsp70 and EpCAM was determined on viable cells using flow cytometry. Moreover,
non-adherent and adherent cells were analyzed separately in A549 cells for their mHsp70 and EpCAM expression. Gray histograms represent isotype control, white
histograms mHsp70 staining and black histograms EpCAM staining. The proportion of cells stained positively for mHsp70 and EpCAM are indicated in each
histogram. The data show one representative result of at least three independent experiments. (C) Representative photomicrographs of untreated and TGFβ treated
A549 cells on day 10, day 10 + 4 days recovery without TGFβ and day 10 + 7 days recovery without TGFβ.
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FIGURE 3 | Recovery of tumor cells from buffer and a mixture with EDTA blood. Two breast cancer cell lines were chosen for the recovery experiments with
cmHsp70.1 mAb-functionalized magnetic bead system: SK-BR-3 with a high surface expression of Hsp70 and T47D with a low surface expression of Hsp70.
(A) Tumor cells were spiked into buffer and incubated with the beads for 1 h at 37◦C. The percentage of recovered cells aligned with the mHsp70 status of the cells
(see Figure 1), as determined by flow cytometry, with 80 ± 11% of SK-BR-3 and 28 ± 13% of T47D cells being recovered. (B) Tumor cells were spiked into blood
from healthy donors after depletion of erythrocytes and incubated with cmHsp70.1 mAb-functionalized magnetic beads for 1 h at 37◦C. Recovery from blood was
very similar to that in buffer, with an 83 ± 5% recovery of SK-BR-3 cells and a 34 ± 7% recovery of T47D cells. Data are from at least 3 independent experiments and
are expressed as means ± SD.
epithelial-like cell population (A549, EpCAM: 64%) compared
to the non-adherent, mesenchymal-like (A549, EpCAM: 46%)
tumor subpopulation that dropped significantly upon treatment
with TGFβ and L-lactic-acid (Figure 2B). Concomitant
with the mesenchymal transition induced by TGFβ and
L-lactic-acid, the number of viable, non-adherent cells in
the A549 cultures increased 15- and 11-fold, respectively.
Similar results were observed for the LS174T cells. Following
treatment with TGFβ and L-lactic-acid, the proportion of
EpCAM positive cells decreased from 100 to 68% and 24%,
respectively, whereas the proportion of cells expressing mHsp70
slightly increased from 76 to 82% and 89%, respectively
(Figure 2B).
Representative photomicrographs illustrating morphological
changes induced by treating A549 cells with TGFβ for 10 days
followed by a recovery period in the absence of TGFβ for 0 (d10),
4 (d10 + 4 days recovery), and 7 (d10 + 7 days recovery) days
are provided in Figure 2C. Following treatment with TGFβ, a
large proportion of cells detaches from the culture flasks and
the remaining adherent cells show a spindle-like phenotype.
Within the recovery period of 4 and 7 days, tumor cells became
adherent and showed an epithelial-like phenotype. Similar
results were observed after treatment with L-lactic-acid (data
not shown).
Recovery of “Spiked” Tumor Cells by
Magnetic Bead-Based Separation System
Depends on the Proportion of mHsp70
Positive Cells
To assess and compare the capacity of cmHsp70.1 mAb coated
magnetic beads to separate CTCs from buffer and peripheral
blood and its relationship with mHsp70 expression, magnetic
beads covalently coupled to cmHsp70.1 mAb were incubated
with buffer and blood from healthy volunteers that had been
“spiked” with identical numbers of SK-BR-3 breast cancer
cells (∼93% positive for mHsp70 expression) or T47D breast
cancer cells (∼23% positive for mHsp70) expression for 1 h
at 37◦C.
As shown in Figure 3, following magnetic separation, the
recovery of SK-BR-3 cells was significantly greater than the
recovery of T47D cells (mHsp70: 80 ± 11% vs. 38 ± 13% and
83 ± 5% vs. 34 ± 7%, respectively) for both experiments (n = 3)
in buffer (Figure 3A) and blood (Figure 3B). Capture therefore
correlated with the percentage of mHsp70 positive cells in the
respective tumor cell populations.
VybrantTM CFDA-Stained and Unstained
Tumor Cells Can Be Recovered With
cmHsp70.1 mAb-Functionalized
CellCollector® System
The primary limitation of most ex vivo CTC isolation
techniques is the relatively small volume of blood which
is used (7.5ml) and the low numbers of CTCs that can
be derived therefrom. The GILUPI CellCollector R© directly
captures tumor cells from the patient’s blood stream using
an EpCAM antibody-coated CellCollector R© system inserted
into the cubital veins over a 30min period. To evaluate
the capacity of adapting this approach to capture cells
expressing mHsp70, the cmHsp70.1 mAb was covalently linked
to the surface of the detector tip of the CellCollector R©
system and this was then incubated with a suspension of
VybrantTM CFDA pre-stained or unstained SK-BR-3 or T47D
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FIGURE 4 | Capture of SK-BR-3 and T47D cells with the cmHsp70.1
mAb-functionalized CellCollector® system. (A) SK-BR-3 cells were stained
with CFSE (green) and incubated with the cmHsp70.1 mAb-functionalized
CellCollector® system. Captured cells were analyzed with a fluorescence
microscope. Scale bar 100µm. (B) SK-BR-3 or T47D cells were incubated
with the cmHsp70.1 mAb-functionalized CellCollector® system for 30min,
fixed and stained with cytokeratin antibodies (CK-FITC, green) and Hoechst
33342 (DAPI, blue). Scale bar 25µm.
cells in buffer. The capture of cells was then determined
using a fluorescence microscope. As shown in Figure 4A, the
cmHsp70.1 mAb-functionalized CellCollector R© system captured
more VybrantTM CFDA pre-stained SK-BR-3 cells than T47D
tumor cells. Similar results were obtained using unstained
tumor cells that were subsequently fixed and stained with a
cocktail of cytokeratin antibodies directly on the cmHsp70.1
mAb-functionalized CellCollector R© system (data not shown).
Representative fluorescence micrographs of SK-BR-3 and T47D
tumor cells on the cmHsp70.1 mAb-functionalized wires
after staining with DAPI and CK-FITC are provided in
Figure 4B.
Tumor Cells Collected With cmHsp70.1
mAb-Functionalized CellCollector® System
From the Blood Maintain Their Phenotype
and Can Be Propagated in Cell Culture
Circulating tumor cells (CTCs) are very rare and further
analysis of these might require the in vitro expansion of
isolated cells. The capacity to transfer cells that have been
captured using the cmHsp70.1 mAb-based CellCollector R©
system into cell culture was therefore evaluated. For this,
the cmHsp70.1 mAb-functionalized CellCollector R© system was
incubated with peripheral blood which had been spiked with
unstained SK-BR-3 breast cancer cells under sterile conditions.
After washing, the functionalized part of the detector was
placed in a cell culture flask with appropriate culture medium.
After 24 h at 37◦C, SK-BR-3 cells became adherent to the
culture flask and started to grow. Flow cytometric analysis
revealed that the phenotype of SK-BR-3 cells that were collected
using the cmHsp70.1 mAb-based CellCollector R© wire system
was comparable to that of SK-BR-3 cells in cell culture
(mHsp70: 94% vs. 91%; EpCAM: 100% vs. 100%, respectively)
(Figure 5).
cmHsp70.1 mAb-Functionalized Magnetic
Beads Can Isolate CTCs From EDTA Blood
of Patients With Squamous Cell Carcinoma
of the Head and Neck (SCCHN) and
Non-small Cell Lung Carcinoma (NSCLC)
Given the rarity of CTCs, it is also important to confirm
that cmHsp70.1 mAb-functionalized magnetic beads can isolate
CTCs from the peripheral blood of patients with cancer.
We obtained EDTA blood from 8 patients with SCCHN,
1 patient with CUP tumor of the head and neck, and 3
patients with advanced NSCLC at diagnosis. The age of the
SCCHN patients ranged between 51 and 72 years and that of
NSCLC patients between 71 and 76. The clinical parameters
of all patients are summarized in Table 1. Using magnetic
bead separation with cmHsp70.1 mAb-functionalized magnetic
beads we succeeded to isolate CTCs from 7 of 8 patients
with SCCHN and from 3 of 3 patients with advanced NSCLC.
The number of CTCs isolated from 7.5ml EDTA blood of
patients which are shown in Table 1 ranged between 0 and 92
cells. Representative fluorescence microscopic views of singular
and clustered CTCs derived from equal amounts of EDTA
blood (7.5ml) of patients with SCCHN and NSCLC isolated
with EpCAM mAb and cmHsp70.1 mAb-functionalized beads
that were counter-stained with DAPI, CK-FITC, EpCAM-PE
are shown in Figures 6A,B. cmHsp70.1 mAb-functionalized
bead-separated, cytokeratin-positive CTCs were either EpCAM-
positive or EpCAM-negative (Figure 6A). In all tested cases,
higher CTC numbers could be isolated from 7.5ml EDTA blood
of patients with SCCHN and NSCLC after separation with
cmHsp70.1 mAb-functionalized magnetic beads compared to
that isolated with EpCAM mAb-functionalized beads (Table 1).
Growth of isolated CTC clones was observed 14 days after
Frontiers in Oncology | www.frontiersin.org 8 November 2018 | Volume 8 | Article 497
Breuninger et al. CTC Isolation via Membrane Hsp70
FIGURE 5 | Capture of SK-BR-3 tumor cells with the cmHsp70.1 mAb-functionalized CellCollector® system and subsequent cultivation and analysis. SK-BR-3 cells
were captured from a mixture of the tumor cell line with EDTA blood. The functional part of the wire was cut from the detector and transferred to a cell culture flask.
Cells that became adherent in the flask were expanded and finally analyzed with flow cytometry. Cells captured with the cmHsp70.1 mAb-functionalized wire (right
panel) showed characteristics comparable to those of SK-BR-3 cells from cell culture (left panel). Gray histograms represent isotype control, white histograms
mHsp70 staining and black histograms EpCAM staining. The numbers in the histograms indicate the proportion of cells stained positive for mHsp70 and EpCAM.
Data are a representative result of at least three independent experiments.
TABLE 1 | Clinical characteristics of patients with squamous cell carcinoma of the head and neck (SCCHN), CUP tumor of the head and neck, and non-small cell lung
carcinoma (NSCLC) assessed for CTC isolation using cmHsp70.1 mAb- and EpCAM mAb-functionalized magnetic beads.
ID Location T N M ECE p16 Grading CTCs CTCs
cmHsp70.1 EpCAM
SCCHN
1 Larynx pT3 pN2c cM0 negative nd 2 nd nd
2 Nose pT1 cN0 cM0 nd nd 2 0 nd
3 Nose pT2 cN0 cM0 nd nd 2 46 nd
4 Tonsils pT2 pN1 cM0 positive positive 2 17 nd
5 Hypopharynx pT2 pN3b cM0 positive nd 2 92 nd
6 Oropharynx pT1 pN0 cM0 negative positive 2 43 29
7 Mouth pT1 pN0 cM0 negative nd 1 9 4
8 Mouth cT3 pN2 cM0 nd nd 2 12 nd
9 CUP cT0 pN3b cM0 positive negative 3 32 nd
ID Location T N M stage PD-L1 CTCs CTCs
Lung lobe cmHsp70.1 EpCAM
NSCLC
1 Upper right cT1a cN2 cM1c IVB 20% 18 7
2 Upper right cT4 cN2 cM1c IVB 90% 45 nd
3 Upper right cT3 cN2 cM1a IVA 30% 35 nd
Patient code (ID), tumor location, TNM stage, extracellular extension (ECE), p16 status, grading, PD-L1 positivity, and CTC counts. CTCs were isolated either with cmHsp70.1 mAb-
and EpCAM mAb-functionalized beads from 7.5ml EDTA blood.
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FIGURE 6 | Capture of CTCs from the EDTA blood of patients using EpCAM mAb- or cmHsp70.1 mAb-functionalized magnetic beads. Representative views of
singular (A) and clustered (B) CTCs derived from EDTA blood (7.5ml, each) of patients with squamous cell carcinoma of the head and neck (SCCHN) and non-small
cell lung carcinoma (NSCLC) bound to the EpCAM mAb- and cmHsp70.1 mAb-functionalized beads: brightfield, DAPI (blue), FITC-labeled cytokeratin antibody
(CK-FITC, green), PE-labeled EpCAM (EpCAM-PE, red), overlay derived thereof. Scale bar 20µm.
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limiting dilution cloning of primary CTCs in 10 of 11 patients
with SCCHN and NSCLC.
Future studies are planned to analyze the molecular
characteristics of mHsp70 positive CTCs in a larger cohort of
patients with different tumor stages, before therapy and in the
follow-up period.
DISCUSSION
Tumor heterogeneity presents a significant barrier to the effective
treatment of cancers in general and aggressive, therapy-resistant
metastatic cancers particularly. Circulating tumor cells (CTCs)
present in the peripheral blood offer an invaluable liquid biopsy-
based approach for interrogating and categorizing disease,
evaluating prognosis and monitoring therapeutic responsiveness
in patients with different cancer entities. Crucially, as the number
of CTCs correlates with the stage of metastasis and is inversely
related to therapeutic outcome, determining the presence, and
interrogating the biology of CTCs provide the insights into the
development and mechanism(s) of metastatic spread (39) and
therapeutic resistance. Both are essential if progress in reducing
cancer mortality is to be made, given that 90% of cancer-related
deaths are due to therapy-resistant metastatic disease rather
than the primary tumor (40). The ability to phenotypically and
genetically profile CTCs from individual patients would provide
an unprecedented insight into the biology of the disease on
an individual basis and would inform and underpin the more
effective delivery of precision-based, individualized medicine.
Currently, existing antibody-based approaches for isolating
CTCs use magnetic beads or particles for the capture and
isolation of CTCs. Cell-Search R©, the current FDA-approved
“gold standard” (22) and the GILUPI CellCollector R© (28) rely
on the cell surface expression of EpCAM (CD326) on the CTCs
that are to be captured (41). However, the expression of EpCAM
is often downregulated on CTCs (2), and is also known to be
downregulated following EMT, a process which is integral to
the transition of adherent tumor cells to a migratory status
which enables them to depart from the primary tumor, enter the
circulation and seed distal sites (2). As cells that have undergone
EMT are those that are mostly involved in the establishment and
progression of metastatic disease, it is essential that strategies for
detecting, isolating and subsequently characterizing these CTCs
are based on approaches that can best capture these cells. It
is therefore essential that tumor markers that are expressed on
CTCs before and after EMT are used as targets for capturing
CTCs.
The search for universal tumor markers has revealed that
the major stress-inducible Hsp70 is frequently expressed on
the plasma membrane of a wide variety of tumor entities,
but not non-transformed cells and tissues (31–33). It has also
been demonstrated that metastases often express higher levels
of mHsp70 compared to the primary tumor (33–36). It is
therefore likely that CTCs will preferentially express mHsp70
over EpCAM.
We have previously reported on the development and
validation of a mouse monoclonal antibody (cmHsp70.1) which
is able to bind to this membrane form of Hsp70 (37). The unique
binding characteristics of this antibodymake it an ideal candidate
for the development of new bead- or wire-based approaches for
capturing CTCs that will not be detected using EpCAM-based
approaches, due to the downregulation of EpCAM expression
after EMT. Herein, we profiled the expression of mHsp70 and
EpCAM by cancer cell lines derived from a range of different
tumor entities and the influence of TGFβ- and L-lactic-acid-
induced EMT on expression and examined the capacity of
bead- and wire-based approaches for capturing cancer cells
differentially expressing mHsp70.
Flow cytometric profiling revealed heterogeneous mHsp70
and EpCAM expression patterns in cancer cell lines, and
it is expected that the level of heterogeneity within and
between different tumor entities will be even more marked in
the clinical setting. Furthermore, we have demonstrated that
although TGFβ- and L-lactic-acid-induced EMT results in a
loss of EpCAM expression, mHsp70 expression is retained.
The recovery of cancer cell lines expressing high and low
levels of mHsp70 from buffer and blood obtained from health
donors into which cancer cell lines had been “spiked” using
cmHsp70.1 mAb-functionalized magnetic beads and a modified
version of the GILUPI CellCollector R© incorporating cmHsp70.1
mAb-mediated capture revealed that, as expected, the yield of
recovered cells closely correlated with the level of mHsp70
expression of the respective cell line.
Since CTCs are typically very rare−1ml of peripheral
blood of patients with metastatic cancer contains <10 CTCs
(9–11, 42)–further analysis and experimentation requires
an ability to expand isolated cells in vitro (43). We could
show that it is possible for CTCs isolated from patients
with SCCHN and NSCLC to be transferred into cell culture
after cmHsp70.1 mAb-mediated capture. Patient-derived
primary CTCs isolated by cmHsp70.1 mAb-functionalized
magnetic beads were either EpCAM-negative or EpCAM-
positive, indicating that a proportion of EpCAM-negative
CTCs cannot be captured using EpCAM-based isolation
methods.
In summary, herein we have shown that cmHsp70.1
mAb-functionalized bead- and wire-based approaches provide
a promising strategy for the detection and isolation of
CTCs from the blood of patients with cancer. This is
especially pertinent and important for the capture of CTCs
that have undergone EMT, as EMT is associated with a
downregulation of EpCAM, the target antigen on which
most antibody-based approaches for capturing CTCs currently
depend. This new approach could therefore improve the
capacity to interrogate the presence and biology of CTCs
and form the basis of a new liquid biopsy-based strategy for
categorizing disease, evaluating prognosis and for predicting
and monitoring therapeutic responsiveness across a range of
aggressive cancers.
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